EMERGENT BIOSOLUTIONS INC (EBS) Stock Fundamental Analysis
USA - NYSE:EBS - US29089Q1058 - Common Stock
10.16 USD
-0.11 (-1.07%)
10.24 USD
+0.08 (+0.79%)
Overall EBS gets a fundamental rating of 4 out of 10. We evaluated EBS against 535 industry peers in the Biotechnology industry. EBS has an average financial health and profitability rating. EBS has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
EBS had positive earnings in the past year.
In the past year EBS had a positive cash flow from operations.
In multiple years EBS reported negative net income over the last 5 years.
In multiple years EBS reported negative operating cash flow during the last 5 years.
1.2 Ratios
With an excellent Return On Assets value of 9.84%, EBS belongs to the best of the industry, outperforming 93.82% of the companies in the same industry.
EBS has a Return On Equity of 26.02%. This is amongst the best in the industry. EBS outperforms 97.00% of its industry peers.
With an excellent Return On Invested Capital value of 6.67%, EBS belongs to the best of the industry, outperforming 93.26% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.84% | ||
| ROE | 26.02% | ||
| ROIC | 6.67% |
ROA(3y)-20.7%
ROA(5y)-8.82%
ROE(3y)-57.28%
ROE(5y)-27.44%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 16.38%, EBS belongs to the top of the industry, outperforming 94.01% of the companies in the same industry.
EBS has a Operating Margin of 12.79%. This is amongst the best in the industry. EBS outperforms 92.88% of its industry peers.
EBS has a better Gross Margin (53.64%) than 76.22% of its industry peers.
EBS's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.79% | ||
| PM (TTM) | 16.38% | ||
| GM | 53.64% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.64%
GM growth 5Y-10.6%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), EBS is destroying value.
The number of shares outstanding for EBS has been increased compared to 1 year ago.
Compared to 5 years ago, EBS has more shares outstanding
EBS has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.57, we must say that EBS is in the distress zone and has some risk of bankruptcy.
EBS's Altman-Z score of 1.57 is fine compared to the rest of the industry. EBS outperforms 65.17% of its industry peers.
EBS has a debt to FCF ratio of 4.31. This is a neutral value as EBS would need 4.31 years to pay back of all of its debts.
EBS has a better Debt to FCF ratio (4.31) than 92.32% of its industry peers.
EBS has a Debt/Equity ratio of 1.25. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of EBS (1.25) is worse than 78.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.25 | ||
| Debt/FCF | 4.31 | ||
| Altman-Z | 1.57 |
ROIC/WACC0.71
WACC9.44%
2.3 Liquidity
A Current Ratio of 5.66 indicates that EBS has no problem at all paying its short term obligations.
With a decent Current ratio value of 5.66, EBS is doing good in the industry, outperforming 61.05% of the companies in the same industry.
EBS has a Quick Ratio of 3.00. This indicates that EBS is financially healthy and has no problem in meeting its short term obligations.
EBS has a Quick ratio of 3.00. This is in the lower half of the industry: EBS underperforms 61.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.66 | ||
| Quick Ratio | 3 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 275.22% over the past year.
Looking at the last year, EBS shows a decrease in Revenue. The Revenue has decreased by -0.54% in the last year.
EBS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.15% yearly.
EPS 1Y (TTM)275.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.63%
Revenue 1Y (TTM)-0.54%
Revenue growth 3Y-16.2%
Revenue growth 5Y-1.15%
Sales Q2Q%-21.34%
3.2 Future
EBS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.93% yearly.
EBS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.53% yearly.
EPS Next Y767.9%
EPS Next 2Y-21.08%
EPS Next 3Y-46.24%
EPS Next 5Y16.93%
Revenue Next Year-26.82%
Revenue Next 2Y-8.09%
Revenue Next 3Y-15.25%
Revenue Next 5Y7.53%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 5.13, the valuation of EBS can be described as very cheap.
99.06% of the companies in the same industry are more expensive than EBS, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 25.83, EBS is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for EBS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.13 | ||
| Fwd PE | N/A |
4.2 Price Multiples
98.69% of the companies in the same industry are more expensive than EBS, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, EBS is valued cheaper than 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.5 | ||
| EV/EBITDA | 4.51 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of EBS may justify a higher PE ratio.
EBS's earnings are expected to decrease with -46.24% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y-21.08%
EPS Next 3Y-46.24%
5. Dividend
5.1 Amount
EBS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
10.16
-0.11 (-1.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners70.25%
Inst Owner Change-0.01%
Ins Owners2.76%
Ins Owner Change0.58%
Market Cap542.04M
Revenue(TTM)1.04B
Net Income(TTM)139.50M
Analysts74.29
Price Target13.77 (35.53%)
Short Float %17.06%
Short Ratio9.38
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)96.05%
Min EPS beat(2)59.77%
Max EPS beat(2)132.33%
EPS beat(4)4
Avg EPS beat(4)292.75%
Min EPS beat(4)59.77%
Max EPS beat(4)868.88%
EPS beat(8)5
Avg EPS beat(8)97.72%
EPS beat(12)5
Avg EPS beat(12)-185.29%
EPS beat(16)7
Avg EPS beat(16)-163.68%
Revenue beat(2)1
Avg Revenue beat(2)-2.12%
Min Revenue beat(2)-4.69%
Max Revenue beat(2)0.46%
Revenue beat(4)1
Avg Revenue beat(4)-7.69%
Min Revenue beat(4)-24.3%
Max Revenue beat(4)0.46%
Revenue beat(8)4
Avg Revenue beat(8)5.39%
Revenue beat(12)7
Avg Revenue beat(12)9.24%
Revenue beat(16)9
Avg Revenue beat(16)4.84%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-209.09%
EPS NQ rev (3m)-204.35%
EPS NY rev (1m)0%
EPS NY rev (3m)66.43%
Revenue NQ rev (1m)-2.51%
Revenue NQ rev (3m)-8.79%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.13 | ||
| Fwd PE | N/A | ||
| P/S | 0.64 | ||
| P/FCF | 3.5 | ||
| P/OCF | 3.21 | ||
| P/B | 1.01 | ||
| P/tB | 8.07 | ||
| EV/EBITDA | 4.51 |
EPS(TTM)1.98
EY19.49%
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)2.91
FCFY28.6%
OCF(TTM)3.17
OCFY31.18%
SpS15.96
BVpS10.05
TBVpS1.26
PEG (NY)0.01
PEG (5Y)N/A
Graham Number21.16
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.84% | ||
| ROE | 26.02% | ||
| ROCE | 8.44% | ||
| ROIC | 6.67% | ||
| ROICexc | 8.41% | ||
| ROICexgc | 15.54% | ||
| OM | 12.79% | ||
| PM (TTM) | 16.38% | ||
| GM | 53.64% | ||
| FCFM | 18.2% |
ROA(3y)-20.7%
ROA(5y)-8.82%
ROE(3y)-57.28%
ROE(5y)-27.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.64%
GM growth 5Y-10.6%
F-Score6
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.25 | ||
| Debt/FCF | 4.31 | ||
| Debt/EBITDA | 3.18 | ||
| Cap/Depr | 13.82% | ||
| Cap/Sales | 1.64% | ||
| Interest Coverage | 2.06 | ||
| Cash Conversion | 80.4% | ||
| Profit Quality | 111.11% | ||
| Current Ratio | 5.66 | ||
| Quick Ratio | 3 | ||
| Altman-Z | 1.57 |
F-Score6
WACC9.44%
ROIC/WACC0.71
Cap/Depr(3y)106.07%
Cap/Depr(5y)126.37%
Cap/Sales(3y)13.29%
Cap/Sales(5y)12.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)275.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.63%
EPS Next Y767.9%
EPS Next 2Y-21.08%
EPS Next 3Y-46.24%
EPS Next 5Y16.93%
Revenue 1Y (TTM)-0.54%
Revenue growth 3Y-16.2%
Revenue growth 5Y-1.15%
Sales Q2Q%-21.34%
Revenue Next Year-26.82%
Revenue Next 2Y-8.09%
Revenue Next 3Y-15.25%
Revenue Next 5Y7.53%
EBIT growth 1Y153.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year347.11%
EBIT Next 3Y55.51%
EBIT Next 5Y39.09%
FCF growth 1Y125.73%
FCF growth 3Y-28.05%
FCF growth 5Y-17.04%
OCF growth 1Y160.44%
OCF growth 3Y-43.25%
OCF growth 5Y-20.77%
EMERGENT BIOSOLUTIONS INC / EBS FAQ
Can you provide the ChartMill fundamental rating for EMERGENT BIOSOLUTIONS INC?
ChartMill assigns a fundamental rating of 4 / 10 to EBS.
What is the valuation status for EBS stock?
ChartMill assigns a valuation rating of 6 / 10 to EMERGENT BIOSOLUTIONS INC (EBS). This can be considered as Fairly Valued.
What is the profitability of EBS stock?
EMERGENT BIOSOLUTIONS INC (EBS) has a profitability rating of 6 / 10.
What is the expected EPS growth for EMERGENT BIOSOLUTIONS INC (EBS) stock?
The Earnings per Share (EPS) of EMERGENT BIOSOLUTIONS INC (EBS) is expected to grow by 767.9% in the next year.